NYSE: RDY
CanSino Biologics Wins NMPA Clearance to Trial 5‑Component DTaP Vaccine (Td5cp) in Children Aged 4–5 – Booster Age Expansion Targets Pre‑School Pertussis Gap
CanSino Biologics Inc. (HKG: 6185) announced that its Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5‑Component) Combined Vaccine has obtained approval from China's National Medical Products Administration (NMPA) to initiate a…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
